ESTRO 2021 Abstract Book

S1006

ESTRO 2021

G3 late toxicity (1: gastric ulcer, 2: stenotic fibrosis, 2: cholangitis) and no late G4 toxicity was recorded. No treatment-related deaths occurred. There was no difference in terms of toxicity profile in patients treated with tomotherapy compared to those treated with VMAT. Conclusion Postoperative intensity-modulated hypofractionated IGRT concomitant to capecitabine in pts with biliary tract carcinoma is feasible with a good toxicity profile despite the large volumes of PTV and despite high dose delivered when SIB was used. PO-1215 Indian experience of 100 HCC patients with portal vein thrombosis treated with robotic radiosurgery D. Dutta 1 , S.K. Reddy 1 , Y. Sreenija 1 , H.M. Nair 1 , A. Sasidharan 1 , A. Gupte 1 , R. Kannan 2 , S.G. Pottayil 2 , A. Edappattu 3 , S. S 4 1 Amrita Institute of Medical Sciences, Radiation Oncology, Kochi, India; 2 Amrita Institute of Medical Sciences, Radiology, Kochi, India; 3 Amrita Institute of Medical Sciences, Medical Physics, Kochi, India; 4 Amrita Institute of Medical Sciences, Surgical Gastroenteology, Kochi, India Purpose or Objective Analysis from a prospective study evaluating the role of Stereotactic body radiotherapy (SBRT) with CyberKnife (CK) in Indian patients suffering from hepatocellular carcinoma with portal vein thrombosis (HCC-PVT). Materials and Methods Patients with inoperable HCC-PVT, good performance score(PS) and liver function are accrued for treatment on CK (version M6) and planned with Multiplan (iDMS V2.0). Triple-phase contrast computed tomography (CT) scan was done for contouring and the gross tumor volume (GTV) included contrast enhancing mass within main portal vein and adjacent parenchymal disease. Dose prescription was as per risk stratification protocol (22- 50Gy in 5 fractions) while achieving the constraints of mean liver dose <15Gy, 800 cc liver <8Gy and the duodenum max of <24 Gy). Results Between Jan 2017 till Dec 2020, 100 consecutive HCC with PVT patients (pt) were accrued [male 97(97%), CP A 66%, CP B 30%, mean age 61.4 years (38-77yrs), CLIP 0-2: 29 (29%), CLIP 3-6 69 (69%), infective etiology 10%, PS0-1 81% ]. In 100 consecutive patients accrued, 70 were evaluable for response assessment (>3 mo follow up). Mean survival was 7.91 mo (3 mo-30 mo), 54 patients expired and 41 were alive. 28 (40%) patients had recanalization of PVT (response), 36 (51%) pts did not recanalize, 3 (4%)pt had progressive disease and 3 (4%) did not have response evaluation. Mean overall survival in responders and non-responders were 10.57 and 6.47 month respectively (p-0.001). Mean survival in patients with PS0, PS1 and PS2 were 16.5, 11 and 10.1 mo (p- 0.039) respectively. Alcohol intake had a trend towards significance (9.3 Vs 14.6 mo; p-0.089). Adjuvant sorafenib, BCLC stage, gender, age, RT dose did not influence response to treatment. Among these 70 evaluable pts, 17pt (24%) had RILD [6 (8%) had Classic RILD & 11 (16%) had non-classic RILD]. CP score assessment at 2 month follow up, 38 (54%) had no change in CP score. Decline of 1, 2 & 3 point CP score from baseline was in 9 (13%), 12 (17%), 13 (19%) pts. Improvement in CP score from baseline in 7(10%). Among 100 patients who underwent fiducial placement, decompensation occurred in 15 patients (15%), 5(5%) had post- fiducial bleed and 1 patient (1%) required embolization. At Post-CK3 month decline from Grade A to B in 20 (28%) and C in 2 (2%). Decline from grade B to C in 4 (6%). Conclusion PVT response or recanalization after SBRT is a statistically significant prognostic factor for survival function in HCC-PVT. PO-1216 Outcomes and prognostic factors in neoadjuvant chemoradiotherapy for resectable esophageal cancer R. Benlloch Rodríguez 1 , A. Valcárcel Díaz 2 , M. López Valcárcel 1 , J. Romero Fernández 1 , S. Córdoba Largo 1 , J.L. Lucena de la Poza 3 , M.D. Chaparro Cabezas 3 , M. Hernández Miguel 1 , B. Gil Haro 1 , S. Santana Jiménez 1 , O. Engel 1 , J.F. Obeso Herrera 1 , C. De La Fuente 1 1 Puerta de Hierro University Hospital, Radiation Oncology, Madrid, Spain; 2 Puerta de Hierro University Hospital, Radiation Oncology, Radiation Oncology, Madrid, Spain; 3 Puerta de Hierro University Hospital, Surgery, Madrid, Spain Purpose or Objective To determine pathological response, downstaging rate, overall survival (OS), local relapse-free survival (LRFS), nodal relapse-free survival (NRFS) and distant metastases-free survival (DMFS) Materials and Methods Between 2012 and 2021, 40 patients (p.) with resectable esophageal cancer were treated in our institution. Males/Females: 33/7. Mean age: 63 yo (39-85). Histology: Adenocarcinoma 27 p. (67.5 %), squamous cell carcinoma 10 p. (25%), poorly differenciated 3 p. (7.5 %). cT stage: T1: 3p. (7.5%), T2: 9p. (22.5%), T3: 28p. (70%). cN stage: N0: 12p. (30%), N1: 16p. (40%), N2: 9 p. (22.5%), N3: 3p. (7.5%). Radiotherapy with IMRT technique up to a mean dose of 43.63 Gy (41.4-50.4) plus weekly carboplatin (2AUC) and paclitaxel (50mg/sqm) followed by McKeown´s total esophaguectomy or Ivor Lewis´s subtotal esophaguectomy. Statistics: Kaplan Meier and long Rank, T-student, Chi square. Results Between 2012 and 2021, 40 patients (p.) with resectable esophageal cancer were treated in our institution. Males / Females: 33/7. Mean age: 63 yo (39-85). Histology: Adenocarcinoma 27 p. (67.5 %), squamous cell carcinoma 10 p. (25%), poorly differenciated 3 p. (7.5 %). cT stage: T1: 3p. (7.5%), T2: 9p. (22.5%), T3: 28p. (70%). cN stage: N0: 12p. (30%), N1: 16p. (40%), N2: 9 p. (22.5%), N3: 3p. (7.5%). Radiotherapy with IMRT technique up to a mean dose of 43.63 Gy (41.4-50.4) plus weekly carboplatin (2AUC) and paclitaxel (50 mg/sqm) followed by McKeown´s total esophaguectomy or Ivor Lewis´s subtotal esophaguectomy. Statistics: